SFSIG
ADMS

San Francisco Sentry Investment Group’s Adamas Pharmaceuticals ADMS Stock Holding History

San Francisco Sentry Investment Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-41
Closed – – 945
2019
Q2 		$0 Hold
41
– – ﹤0.01% 1017
2019
Q1 		$0 Hold
41
– – ﹤0.01% 1094
2018
Q4 		$0 Buy
+41
New +$533 ﹤0.01% 1106

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

San Francisco Sentry Investment Group's ADMS Position: Q3 2019 in Review

San Francisco Sentry Investment Group sold out of Adamas Pharmaceuticals (ADMS) in Q3 2019, closing a stake of 41 shares.

San Francisco Sentry Investment Group first reported a position in ADMS in Q4 2018 and held it in 3 quarters. The position peaked at $0 in Q2 2019. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

  • San Francisco Sentry Investment Group reported no remaining Adamas Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 41 Adamas Pharmaceuticals shares in Q3 2019.
  • San Francisco Sentry Investment Group first reported a position in Adamas Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • San Francisco Sentry Investment Group's Adamas Pharmaceuticals position peaked at $0 in Q2 2019.
  • 87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q3 2019, filed 18 Oct 2019.